Abbisko Cayman Limited provided unaudited Group earnings guidance for the six months ended June 30, 2024. Based on the preliminary review of the Group's unaudited management accounts for the six months ended June 30, 2024, (i) the total revenue of the Group for the six months ended June 30, 2024 is expected to be approximately RMB 497 million, representing an increase of RMB 478 million from approximately RMB 19 million for the six months ended June 30, 2023; and (ii) the Group is expected to record a profit for the period within the range of RMB 200 million to RMB 220 million for the six months ended June 30, 2024, compared to a loss for the period of approximately RMB 209 million for the six months ended June 30, 2023. Apart from the improved cost control through enhanced business operation efficiency, the anticipated increase in total revenue and turnaround from loss to profit were also mainly attributable to the out-licensing agreement for pimicotinib (ABSK021) and the upfront payment of USD 70 million (RMB 497 million) with MERCK HEALTHCARE KGAA, which contributed significantly to the revenue for the six months ended June 30, 2024.